# Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

Source: https://onco.cc/trials/nct07718243/  
OnCo record `nct07718243` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by Institute of Cancer Research, United Kingdom, now recruiting.

## Summary

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC is a phase 1/2, interventional study registered as NCT07718243 by Institute of Cancer Research, United Kingdom, with a registry enrolment figure of 62 participants, started 2026-08-28 and due to reach its primary completion in 2030-01-31. Interventions recorded: Bexmarilimab 1mg/kg and nivolumab 1mg/kg; Bexmarilimab 3mg/kg and nivolumab 1mg/kg; Recommended Phase II Dose. Conditions listed: Melanoma (Skin Cancer); Non Small Cell Lung Cancer; Solid Tumor in Advanced Stage. Primary outcome: To establish a recommended Phase II dose (RP2D) of bexmarilimab in combination with nivolumab; Determining causality of each adverse event to bexmarilimab and nivolumab and grading severity according to the NCI CTCAE Version 5.0; Evaluation of disease response by RECIST criteria version 1.1, immune-. Lung eligibility wording from the registry: "Part B1: Histologically proven NSCLC". Sites: United Kingdom. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: BLAZE
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07718243
- Phase: 1/2
- Setting: A Phase I/II Trial of Bexmarilimab and Nivolumab in Patients With Solid Tumours, Non-Small Cell Lung Cancer and Melanoma
- Sponsor: Institute of Cancer Research, United Kingdom
- Enrolled: 62

## Notes

- UK sites (registry): The Christie NHS Foundation Trust (Manchester); The Royal Marsden NHS Foundation Trust - Drug Development Unit (Sutton).

## Sources

- ClinicalTrials.gov NCT07718243: https://clinicaltrials.gov/study/NCT07718243

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Faron Pharmaceuticals](https://onco.cc/companies/faron-pharmaceuticals/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07718243.json